Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Citi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2015-12-23 11:30:40 |
Versijas komentārs | |
Teksts |
Olaine, December 23, 2015
Olainfarm Tentatively Plans
the Sales Increase of 3% for 2016
Preliminary
plans of AS Olainfarm for 2016 provide for sales increase of 3%
while profit could remain at the levels forecast for 2015 of 15
million euros, or even slightly shrink. More precise forecasts will
be approved by an AGM of Olainfarm to be held in June 2016.
Annual General
Meeting of shareholders of JSC Olainfarm, held on June 11, 2015
approved operating plan of the company, according to which the
unconsolidated sales of the company in 2015 will reach 87 million
euros, while consolidated sales will reach 100 million euro.
According to these preliminary sales figures, in eleven months of
2015, the company has attained 91% of annual target for
unconsolidated sales and 90% of annual target for consolidated
sales.
In eleven
months of 2015 according to preliminary results, consolidated sales
of AS “Olainfarm” have reached 90.19 million euros, which
represents an increase by 6% compared to the same period in
2014. According to preliminary figures the unconsolidated
sales of the company have reached 79.59 million euros, which
represents an increase by 8% compared to eleven months of 2014.
JSC Olainfarm is one of the
biggest pharmaceutical companies in Latvia with more than 40 years
of experience in production of medication and chemical and
pharmaceutical products. A basic principle of company's operations
is to produce reliable and effective top quality products for
Latvia and the rest of the world. Products made by the Group are
being exported to more than 35 countries of the world, including
the Baltics, Russia, other CIS, Europe, Asia, North America and
Australia. Information
prepared by: |
Pielikumi |
|